Enzyme-treated product or extract of Aralia elata

Abstract

To provide an enzyme-treated material derived from Aralia elata or its extract and a method for producing the same, and a novel composition that comprises the same as an active ingredient and has beneficial actions such as skin aging prevention.SOLUTION: The present invention relates to a material prepared by treating Aralia elata with one or more enzymes selected from the group consisting of cellulase, chitinase and protease, or its extract, a composition containing the treated material or extract, and a method for producing the treated material or extract.SELECTED DRAWING: Figure 1

Description

Technical Field

[0001] The present invention relates to an enzymatically treated product or extract of Castanopsis sieboldii, a method for producing the same, and a composition containing the treated product or extract, which can be used as an external preparation for skin, skin cosmetics, and the like.

Background Art

[0002] Care for aging and suppression of disorders caused by aging are matters of high interest regardless of gender, and various products such as cosmetics, supplements, beverages, and food products that claim anti-aging and anti-aging effects are in circulation. It is said that as the amount of sebum and moisture in the skin decreases with aging, the moisturizing power of the stratum corneum on the skin surface is lost, and fine wrinkles and skin roughness due to dryness are likely to occur.

[0003] In addition, oxidative damage by reactive oxygen species is one of the major causes of aging. Reactive oxygen species are highly reactive and denature and damage biological tissue components by oxidizing them. Oxidative damage by reactive oxygen species is the cause of Alzheimer's disease, Parkinson's disease, Lewy body disease, amyotrophic lateral sclerosis, cataract, arteriosclerosis, diabetic nephropathy, myocardial infarction, rheumatism, etc., and is also greatly involved in aging phenomena in the skin, that is, wrinkles, sagging, dullness, spots, etc. (Non-Patent Document 1).

[0004] Factors that increase reactive oxygen species include aging, excessive exercise, ultraviolet exposure, and mental stress. However, an increase in reactive oxygen species causes the accumulation of oxidized proteins in the living body, so-called abnormal proteins, and causes the aforementioned diseases (Non-Patent Document 2). Particularly in the skin, the influence of oxidative damage due to ultraviolet exposure is large, DNA damage occurs in epidermal keratinocytes and skin fibroblasts, etc., and the decomposition of elastic components of the skin, elastin and collagen, occurs, promoting wrinkles and spots (Non-Patent Document 3).

[0005] The proteasome, an enzyme, is known to remove abnormal proteins in the body caused by oxidative damage from reactive oxygen species. The proteasome, whose physiological function has been studied in recent years, is a large multi-component complex that removes abnormal proteins that interfere with normal folding and molecular assembly during the process of protein formation into three-dimensional structure, and plays a role in protein quality control. In the skin, it is known that proteasome activity decreases and oxidized collagen increases with age (Non-Patent Literature 4). Examples of applications in skin cosmetics as anti-aging agents that promote proteasome activity include one or two abnormal protein removers selected from silibin, Bletilla striata extract, and Iris extract (Patent Literature 1), solvent extract formulations of Ganoderma lucidum (Patent Literature 2), and peach extract belonging to the Rosaceae family (Patent Literature 3).

[0006] Furthermore, sirtuins, which have recently attracted attention from the perspective of anti-aging, are a type of histone deacetylase that plays an important role in the regulation of gene transcription, such as protecting telomeres. In humans, seven types, SirT1-7, have been identified to date. In particular, sirtuin I (SIRT1) has been shown to have various functions, including anti-aging effects, diabetes improvement effects, cardiovascular protective effects, renal disease improvement effects, suppression of inflammatory cytokine production, and neuroprotective effects. In addition, compounds such as resveratrol and quercetin are being studied as enhancers of SIRT1 deacetylation activity for use as anti-aging agents, diabetes treatments, cardiovascular disease treatments, neurological disease treatments, and anti-inflammatory agents (Non-patent Literature 4).

[0007] Examples of applications of sirtuin I (SIRT1) activators in skin cosmetics include a cosmetic containing kudzu extract as an active ingredient (Patent Document 4), an activator containing a lignin glycoside derived from Japanese white pine as an active ingredient (Patent Document 5), and a skin cosmetic containing kiwi and / or senna extract (Patent Document 6).

[0008] Aralia elata, also used as a raw material for herbal medicine, is a deciduous shrub belonging to the Araliaceae family, distributed in East Asia, including Hokkaido, Honshu, Shikoku, Kyushu, Okinawa, the Korean Peninsula, China, the Kuril Islands, and Sakhalin. Its young shoots are called "taranome" and are consumed as food.

[0009] Since ancient times, the bark and root bark of the Japanese angelica tree (Aralia elata) have been used as herbal medicines. It has been believed that decocting the dried bark of the Japanese angelica tree and consuming it is effective for lowering blood sugar, improving digestion, regulating bowel movements, and treating diabetes and kidney disease.

[0010] To date, efforts to use Aralia elata, which has medicinal properties as a herbal medicine, as a cosmetic ingredient have been considered and reported. For example, Patent Document 7 shows a hair-nourishing cosmetic for preventing hair loss and promoting hair growth, which contains Aralia elata extract along with its main components. Patent Document 8 shows cosmetics and foods that exhibit hyaluronidase inhibitory activity, which contain Aralia elata extract, and suggests the possibility of improving skin itchiness by incorporating the extract into cosmetics. Patent Document 9 shows that therapeutic agents and cosmetics containing extracts from plants including the Aralia genus have an inhibitory effect on keratinocyte proliferation, and shows cosmetics that suppress changes in skin appearance accompanied by abnormal keratinocyte proliferation. Furthermore, Patent Document 10 shows the use of Aralia elata powder and extract in cosmetics that have an effect of improving rough skin and preventing inflammation.

[0011] In developing this product for anti-aging, we conducted a prior art review to prepare control samples. For example, Patent Document 11 shows that cultures of Geotricum candidum in a culture medium containing skim milk have preventive and therapeutic effects on reducing wrinkles, restoring elasticity, and treating blemishes and rough skin. This indicates that its application to topical skin preparations was advanced even before the term "anti-aging" became commonplace. Geotricum candidum is known today by the classification name Galactomyces candidas, and its culture extract is believed to have anti-aging effects. [Prior art documents] [Patent Documents]

[0012] [Patent Document 1] Japanese Patent Publication No. 2007-99650 [Patent Document 2] Japanese Patent Publication No. 2002-29996 [Patent Document 3] Japanese Patent Publication No. 2016-124827 [Patent Document 4] Japanese Patent Publication No. 2010-270012 [Patent Document 5] Japanese Patent Publication No. 2014-185170 [Patent Document 6] Japanese Patent Publication No. 2020-189802 [Patent Document 7] Japanese Patent Application Publication No. 3-284614 [Patent Document 8] Japanese Patent Application Publication No. 6-329544 [Patent Document 9] Japanese Patent Publication No. 2010-189287 [Patent Document 10] Japanese Patent Publication No. 2010-241779 [Patent Document 11] Japanese Patent Application Publication No. 56-36419 [Non-patent literature]

[0013] [Non-Patent Document 1] Mechanisms and Control of Aging, edited by Daisaburo Fujimoto, IPC Co., Ltd., June 30, 1993. [Non-Patent Document 2] BIO Clinica, Vol. 11, No. 5, 1996 [Non-Patent Document 3] Advances and Future Prospects of Cosmetic Efficacy and Evaluation Technology, edited by the Japan Society of Cosmetic Chemists, Yakuji Nippo Co., Ltd., 2001, Kyoritsu Shuppansha. [Non-Patent Document 4] Experimental Medicine, Vol. 28, No. 19, 2010, pp. 3068-3076 [Overview of the Initiative] [Problems that the invention aims to solve]

[0014] According to these conventional findings, the effects of the extract of Aralia elata as a skin cosmetic are mainly expected to prevent inflammation derived from saponin of the components containing Aralia elata, and the actions and effects contributing to anti-aging and anti-aging have not been studied. In addition, regarding the application to a 20S proteasome activity promoter or a sirtuin I (SIRT1) activator, cases using plants of the Araliaceae family or Aralia elata as raw materials have not been studied.

[0015] In addition, as a crude drug, an extract of Aralia elata by ordinary hot water is generally known, but since the bark and branch parts have a structure in which cellulose and hemicellulose form a strong tissue with lignin, it is not an efficient method from the viewpoint of the extraction amount of active ingredients, and improvement of the extraction efficiency of active ingredients has been desired. Therefore, an object of the present invention is to provide a fermented product of Aralia elata by a microorganism that produces one or more enzymes selected from the group consisting of cellulase, chitinase, and protease, or an extract thereof, and a manufacturing method thereof, and a novel composition having the fermented product or the extract as an active ingredient and having beneficial effects such as preventing skin aging.

Means for Solving the Problems

[0016] As a result of intensive studies by the present inventors, a fermented product of Aralia elata by a microorganism that produces one or more enzymes selected from the group consisting of cellulase, chitinase, and protease has an action of increasing the activity of 20S proteasome that promotes the degradation of aging proteins in skin tissue cells, and an action of activating the SIRT1 gene and promoting its expression, and has been found to have an action of suppressing and improving skin aging, leading to the completion of the present invention. The present invention includes the following.

[0017] (1) A processed product of Aralia elata by one or more enzymes selected from the group consisting of cellulase, chitinase, and protease, or an extract thereof. (2) The processed product or extract according to (1), wherein the processed product is a fermented product of Aralia elata by a microorganism that produces the enzyme. (3) The treated product or extract according to (2), wherein the microorganism is one or more microorganisms belonging to the genera Aspergillus, Trichoderma, or Penicillium. (4) The processed product or extract according to any one of (1) to (3), wherein the extract is an extract of the processed product with one or more solvents selected from the group consisting of water, hydrophilic organic solvents, and a mixed solvent of water and a hydrophilic organic solvent. (5) A composition comprising any of the processed product or extract described in (1) to (4). (6) The composition described in (5), which is a topical skin preparation. (7) The composition described in (5), which is a skin cosmetic. (8) A composition according to any one of (5) to (7) for anti-aging. (9) A composition according to any one of (5) to (8) for improving the activity of the 20S proteasome. (10) A composition according to any one of (5) to (9) for promoting the expression of the sirtuin I gene.

[0018] (11) A method for producing a processed product or extract according to any one of (1) to (4), comprising an enzyme treatment step of subjecting Aralia elata to a reaction with one or more enzymes selected from the group consisting of cellulase, chitinase and protease to obtain a processed product of Aralia elata with the enzyme. (12) The method according to (11), wherein the enzyme treatment step includes culturing microorganisms that produce the enzyme in a culture medium containing Aralia elata to obtain a fermentation product of Aralia elata by the microorganisms. (13) The method according to (12), wherein the microorganism is one or more microorganisms belonging to the genera Aspergillus, Trichoderma, or Penicillium. (14) The method according to any one of (11) to (13), further comprising an extraction step of subjecting the treated product to an extraction treatment with one or more solvents selected from the group consisting of water, hydrophilic organic solvents, and a mixed solvent of water and hydrophilic organic solvents to obtain an extract. [Effects of the Invention]

[0019] In preferred embodiments of the processed product or extract according to the present invention, it has a high proteasome activity-enhancing effect and a sirtuin I (SIRT1) activation effect, and has skin condition-improving effects such as anti-aging and anti-aging, and is useful as an active ingredient in compositions used as topical skin preparations or skin cosmetics.

[0020] In particular, the fermented product of Aralia elata using microorganisms that produce specific enzymes exhibits a higher 20S proteasome activity enhancement effect and sirtuin I (SIRT1) expression promotion effect compared to Aralia elata extract that has not undergone fermentation treatment, and is extremely superior in improving skin condition, including anti-aging and anti-aging effects. [Brief explanation of the drawing]

[0021] [Figure 1] Figure 1 shows the results of measuring 20S proteasome activity in fibroblasts cultured in media containing different concentrations of fermentation products of Aralia elata and irradiated with UVB. [Figure 2] Figure 2 shows the results of measuring the mRNA expression level of sirtuin I (SIRT1) in normal human fibroblast cells NB1RGB cultured in a culture medium containing the fermentation product of Aralia elata, under conditions of UVB irradiation (UVB(+)) and conditions without UVB irradiation (normal culture). [Modes for carrying out the invention]

[0022] One or more preferred embodiments of the present invention will be described in detail below.

[0023] 1. Characteristics of enzyme-treated products or extracts of Aralia elata. One or more embodiments of the present invention relate to a product or extract thereof of Aralia elata treated with one or more enzymes selected from the group consisting of cellulase, chitinase, and protease, and a method for producing the same. The product is particularly preferably a fermentation product of Aralia elata by microorganisms that produce the enzymes.

[0024] Here, the parts of the Aralia elata tree used as raw material can include the branches, bark, and root bark. For Aralia elata, logs cultivated for the cultivation of Aralia elata buds or for Aralia elata tea may also be used. The Aralia elata may also have bark and leaves attached. From the viewpoint of improving extraction efficiency, dried, crushed, or pulverized Aralia elata is preferred. Dried, crushed, or pulverized Aralia elata is sometimes referred to as "crushed" or "pulverized" Aralia elata.

[0025] It is preferable to sterilize Aralia elata in the form of pulverized or crushed material before subjecting it to the enzymatic reaction in order to reduce the risk of bacterial growth during the enzymatic treatment. In this case, the pulverized or crushed Aralia elata may be sterilized individually, or it may be dispersed in water and then sterilized. Sterilization can be carried out by any method such as heat sterilization, ultraviolet sterilization, radiation sterilization, or ozone sterilization. For example, water containing Aralia elata may be heat-sterilized at 65°C or higher, for example, 110-130°C or 120-130°C, and in one example, it can be sterilized by treatment at 121°C for 20 minutes. After heat sterilization, it is preferable to cool it to at least the optimal temperature for the enzyme before using it in the reaction.

[0026] The processed product of Aralia elata can be obtained by an enzyme treatment step, in which Aralia elata is subjected to a reaction with one or more enzymes selected from the group consisting of cellulase, chitinase, and protease to obtain the processed product of Aralia elata with the enzyme. Here, the enzyme treatment step may be a step in which commercially available enzymes derived from microorganisms are applied to Aralia elata, but preferably, it is a step in which microorganisms that produce the enzyme are cultured in a culture medium containing Aralia elata to obtain the fermentation product of Aralia elata by the microorganism. As the microorganisms that produce the enzyme, filamentous fungi are preferred, and in particular, one or more microorganisms belonging to the genera Aspergillus, Trichoderma, or Penicillium are preferred. Two or more microorganisms may be combined. As for microorganisms belonging to the genus Aspergillus, Aspergillus oryzae, aSpergillus acretus and Aspergillus niger are preferred. As microorganisms belonging to the genus Trichoderma, Trichoderma liesei and Trichoderma atribilide are preferred. As microorganisms belonging to the genus Penicillium, Penicillium paprogenium, Penicillium decandens and Penicillium funiculum are preferred. The enzyme is preferably derived from these microorganisms, but is not limited thereto, and may be derived from other microorganisms or from animals.

[0027] Next, a preferred embodiment of the process of culturing microorganisms that produce the enzyme in a culture medium containing Aralia elata to obtain a fermentation product of Aralia elata by the microorganisms will be described.

[0028] The culture medium containing Aralia elata is preferably a medium suitable for ordinary filamentous fungi, and typical examples include a medium containing yeast extract, peptone, etc., in addition to sugars such as glucose. The culture temperature is not particularly limited, as long as it is a temperature at which filamentous fungi can grow, but it is typically 15 to 45°C, preferably 25 to 40°C, for example 28 to 37°C. The pH during culture is not particularly limited, as long as it is a pH at which filamentous fungi can grow, but it is 3.0 to 6.0, preferably 4.0 to 7.0, for example 5.0 to 6.0.

[0029] Furthermore, when treating Aralia elata with the aforementioned enzyme, commercially available industrial enzymes may be added to assist the activity of the enzyme. For example, enzyme preparations derived from filamentous fungi such as Sumizyme CG (Shin Nippon Chemical Industries), Cellulase SS (Nagase ChemteX), and Sucrase C (Mitsubishi Chemical) can be used.

[0030] Furthermore, when treating the Aralia elata with the enzyme without microbial fermentation, the temperature is not particularly limited, but is typically 30-70°C, preferably 40-60°C, for example, 45-55°C. The pH during the reaction is not particularly limited, as long as it is a pH at which activity can be maintained, but can be 3.0-8.0, preferably 4.0-6.0.

[0031] The enzyme treatment step may further include enzyme deactivation treatment of the Aralia elata after enzyme treatment (including enzyme treatment by microbial fermentation). Enzyme deactivation treatment can typically be carried out at a temperature of 60 to 121°C, preferably 80 to 110°C, for example, 90 to 100°C. The duration of the enzyme deactivation treatment is not particularly limited, as long as sufficient deactivation is achieved, but it can be 15 minutes to 2 hours, preferably 30 minutes to 1 hour.

[0032] The enzyme treatment step may further include a step of purifying the Aralia elata after enzyme treatment (including enzyme treatment by microbial fermentation). The purification method is not particularly limited.

[0033] If the product of Aralia elata treated with the enzyme is a fermentation product of Aralia elata by microorganisms, the culture medium containing Aralia elata and the microorganisms may be diluted, concentrated, or dried as needed after culturing the microorganisms. When diluting, water or any other solvent can be used, for example. When concentrating, methods such as heat evaporation concentration, freeze concentration, ultrafiltration, dialysis, and chromatography can be used. When drying, methods such as freeze drying (e.g., vacuum freeze-dried products) or heat drying (e.g., spray drying) can be used.

[0034] The composition according to this embodiment preferably contains an extract of the product of Aralia elata treated with the enzyme as an active ingredient. This extract can be prepared by subjecting the product of Aralia elata treated with the enzyme to an extraction treatment with an extraction solvent.

[0035] The extraction solvent is not particularly limited, but is preferably one or more solvents selected from the group consisting of water, hydrophilic organic solvents, and mixed solvents of water and hydrophilic organic solvents. Examples of hydrophilic organic solvents include monohydric alcohols such as ethanol and propanol, and polyhydric alcohols such as glycerin, 1,3-butylene glycol, propylene glycol, and pentanediol.

[0036] The extraction process can typically be carried out at temperatures of -20°C to 100°C, preferably 0°C to 80°C, and more preferably 20°C to 40°C. The extraction time can be set arbitrarily, but it is most preferable to extract for 12 to 96 hours.

[0037] If necessary, the extract obtained by the extraction process may be subjected to wintering (dewaxing). That is, the obtained extract can be cooled to precipitate components that solidify at low temperatures (wax), and the wax can be removed by solid-liquid separation using means such as filtration.

[0038] The extract of the Aralia cordata treated with the aforementioned enzyme may be further diluted, concentrated, or dried after extraction, depending on the purpose, and any dilution, concentration, or drying method can be used for this purpose. When diluting, for example, water or any other solvent can be used. When concentrating, for example, heating evaporation concentration, freeze concentration, ultrafiltration, dialysis, chromatography, etc. When drying, for example, freeze drying such as vacuum freeze-drying, or heat drying such as spray drying can be used.

[0039] The extract of the Aralia cordata treated with the aforementioned enzyme can be further purified as needed. The purification method is not particularly limited, but examples include filtration using a filter such as centrifugal filtration or a membrane filter.

[0040] The product of Aralia elata treated with the enzyme or its extract obtained by the above procedure can be further sterilized or disinfected as necessary. Any sterilization or disinfection method can be applied for sterilization or disinfection. Examples of sterilization or disinfection methods include heat sterilization, filter sterilization, ultraviolet sterilization, radiation sterilization, and ozone sterilization.

[0041] The product of Aralia elata treated with the enzyme or its extract obtained by the above procedure can be further deodorized and / or decolorized as needed. The deodorization and / or decolorization can be carried out by any deodorization and / or decolorization method. For example, a deodorization and / or decolorization method may be used, in which the extract is passed through activated carbon to adsorb odor components and coloring components onto the activated carbon.

[0042] 2. Characteristics of compositions containing enzyme-treated or extract-like products of Aralia elata. Next, preferred embodiments of the use of compositions containing a product of Aralia elata treated with one or more enzymes selected from the group consisting of cellulase, chitinase, and protease, or an extract thereof, will be described.

[0043] The product of Aralia elata treated with the aforementioned enzyme or its extract has the effect of improving 20S proteasome activity and promoting sirtuin I (SIRT1) gene expression, and has excellent skin condition improvement effects such as anti-aging and anti-aging effects on the skin.

[0044] Therefore, the composition is preferably a topical skin preparation or a skin cosmetic. Depending on the final form, such as a topical skin preparation or skin cosmetic, the composition may contain other components in addition to the enzymatic treatment of Aralia elata or its extract.

[0045] Here, "topical skin preparations" refers to pharmaceuticals containing active ingredients (active substances) effective in diagnosing, treating, or preventing diseases in humans or animals, or bases used in such pharmaceuticals. For example, "topical skin preparations" includes pharmaceuticals and quasi-drugs as defined in Japan's "Act on Securing Quality, Efficacy and Safety of Pharmaceuticals, Medical Devices, etc." On the other hand, "cosmetics" refers to cosmetics used on human skin that are not classified as pharmaceuticals or quasi-drugs. "Topical skin preparations" in this context includes cosmetics used on human skin as defined in Japan's "Act on Securing Quality, Efficacy and Safety of Pharmaceuticals, Medical Devices, etc."

[0046] Topical skin preparations may be in any dosage form, such as ointments, patches, poultices, liniments, lotions, creams, extracts, fluid extracts, tinctures, elixirs, syrups, lemonades, aromatic waters, liquids, suspensions, emulsions, medicated bath additives, medicated shampoos, aerosols, powders, granules, tablets, capsules, etc.

[0047] Furthermore, skin preparations or skin cosmetics may be compositions in any form, such as solutions, suspensions, emulsions, powders, pastes, mousses, or gels. In particular, skin cosmetics may be in any form that can be used in contact with the skin, and specifically, examples include lotions, emulsions, serums, general creams (face creams, hand creams, body creams, etc.), facial cleansers (cleansing creams, etc.), packs, shaving creams, sunscreens, sunscreen creams, sunscreen lotions, tanning lotions, cosmetic soaps, foundations, face powders, powders, lipsticks, lip balms, eyeliners, eye creams, eyeshadows, mascaras, bath additives (bath products), shampoos, hair rinses, hair treatments, hair packs, scalp care products, body rinses, body gels, hair dyes, and hair cosmetics. Lotions, emulsions, serums, face creams, and facial cleansers are particularly preferred.

[0048] Furthermore, in compositions according to this embodiment, such as topical skin preparations and skin cosmetics, the enzyme-treated product of Aralia elata or its extract can be incorporated in any form. For example, it may be simply mixed with other ingredients as is, or it may be incorporated in the form of a gel, powder, granules, or capsule.

[0049] The skin cosmetic may contain, in addition to the enzymatic treatment of Aralia elata or its extract, additives permitted in cosmetics, and other active ingredients as needed. Such additives and other active ingredients may be arbitrarily selected and used in a manner suitable for the application and form. The skin cosmetic may be manufactured according to any cosmetic manufacturing method, for example, by mixing, stirring, molding, filling, etc., the raw materials.

[0050] The topical skin preparation may be a composition containing the enzyme-treated product of Aralia elata or an extract thereof as a main ingredient for improving excellent skin conditions such as preventing skin aging and anti-aging. Alternatively, the topical skin preparation may be a composition containing a predetermined pharmacokinetic ingredient (main ingredient) and the enzyme-treated product of Aralia elata or an extract thereof as a base for maintaining and improving skin conditions such as improving skin texture and moisturizing effects. In addition to the enzyme-treated product of Aralia elata or an extract thereof, the topical skin preparation may contain pharmaceutically acceptable additives and, if necessary, other active ingredients. Such additives and other active ingredients can be arbitrarily selected and used in accordance with the use and form of the pharmaceutical. The pharmaceutical according to the present invention can be manufactured by mixing, stirring, molding, filling, etc., the raw materials according to any pharmaceutical manufacturing method.

[0051] The compositions according to this embodiment, such as topical skin preparations and skin cosmetics, may contain one or more additives for formulation, such as carriers (solid or liquid carriers), excipients, surfactants, binders, disintegrants, lubricants, deodorizers, solubilizers, suspending agents, coating agents, pH adjusters, colorants, fragrances, flavoring agents, cooling agents, stabilizers, foaming agents, preservatives, and buffering agents.

[0052] The compositions according to this embodiment, such as topical skin preparations and skin cosmetics, may contain, for example, one or more components arbitrarily selected from the following groups: Any component selected from proteins and protein hydrolysates, such as collagen, collagen hydrolysates, gelatin, gelatin hydrolysates, elastin, elastin hydrolysates, lactoferrin, keratin, keratin hydrolysates, casein, albumin, royal jelly-derived protein hydrolysates, honey-derived protein hydrolysates, etc. Any component selected from natural polymers and their derivatives, such as sodium hyaluronate and hyaluronic acid derivatives, xanthan gum, carrageenan, guar gum, alginic acid and its salts, pectin, chondroitin sulfate and its salts, water-soluble chitin, chitosan derivatives and its salts, pullulan, deoxyribonucleic acid, acacia gum, tragacanth gum, etc. Any component selected from crude drugs, such as Chinese lantern plant, monk fruit, jujube, Job's tears, licorice, Eucommia ulmoides, ginger, and Japanese angelica tree, etc. It may contain any component selected from seaweed powder, seaweed extract, and polysaccharides derived from seaweed. It may contain any component selected from animal-derived substances such as placenta extract. It may contain any component selected from water such as carbonated water, hot spring water, micro-nanobubble water, purified water, and distilled water. It may contain any component selected from acidic polymers such as carboxyvinyl polymer and its salts, polyacrylic acid and its salts, carboxymethylcellulose and its salts, and neutral polymers such as polyvinyl alcohol, hydroxyethylcellulose, hydroxypropylcellulose, methylcellulose, polyethylene glycol, polyvinylpyrrolidone, and nitrocellulose polyvinyl methyl ether. It may contain any component selected from cationic polymers such as cationized cellulose, polyethyleneimine, and cationized guar gum. It may contain any component selected from lower alcohols such as ethanol and isopropyl alcohol. It may contain any component selected from ultraviolet absorbers such as para-aminobenzoic acid-based ultraviolet absorbers, salicylic acid-based ultraviolet absorbers, cinnamic acid-based ultraviolet absorbers, anthranieric acid-based ultraviolet absorbers, and benzophenone-based ultraviolet absorbers.It may contain any component selected from anti-inflammatory agents such as glycyrrhizic acid and its salts, guaiazulene and its derivatives, and allantoin. It may contain any component selected from antioxidants such as stearate esters, nordihydroguaceretenoic acid, dibutylhydroxytoluene, butylhydroxyanisole, parahydroxyanisole, propyl gallate, sesamol, sesamolin, and gossypol. It may contain any component selected from parabenzoic acid esters such as methyl parabenzoate, ethyl parabenzoate, propyl parabenzoate, and butyl parabenzoate, and preservatives such as sorbic acid, dehydroacetic acid, phenoxyethanol, and benzoic acid. It may contain any component selected from edetic acid and its salts such as edetic acid and disodium edetate, and metal ion sequestering agents such as phytic acid and hydroxyethanedisulfonic acid. It may contain any component selected from polyhydric alcohols such as glycerin, 1,3-butylene glycol, and propylene glycol. It may contain any component selected from amino acids such as L-aspartic acid, DL-alanine, L-arginine, L-cysteine, L-glutamic acid, and glycine, and their salts. It may contain any component selected from sugars such as maltitol, sorbitol, xylobiose, N-acetyl-D-glucosamine, and honey. It may contain any component selected from bases such as ammonia water, monoethanolamine, triethanolamine, sodium hydroxide, and potassium hydroxide. It may contain any component selected from hydrocarbons such as liquid paraffin, squalane, and petrolatum. It may contain any component selected from oils and fats such as coconut oil, evening primrose oil, jojoba oil, castor oil, and hydrogenated castor oil. It may contain any component selected from fatty acids such as lauric acid, myristyl acid, palmitic acid, stearic acid, and behenic acid. It may contain any component selected from higher alcohols such as myristyl alcohol, cetanol, cetostearyl alcohol, stearyl alcohol, and behenyl alcohol. It may contain any component selected from esters such as isopropyl myristate, isopropyl palmitate, cetyl octanoate, glyceryl trioctanoate, octyldodecyl myristate, octyl stearate, and stearyl stearate.It may contain any component selected from phospholipids such as lecithin and its derivatives. It may contain any component selected from animal and plant-derived lipids such as bovine bone marrow lipid and bovine brain lipid. It may contain any component selected from alkyl sulfates such as ammonium lauryl sulfate, lauryl sulfate ethanolamine, sodium lauryl sulfate, and lauryl sulfate triethanolamine. It may contain any component selected from polyoxyethylene alkyl sulfates such as polyoxyethylene (2EO) lauryl ether sulfate triethanolamine (where EO is ethylene oxide, and the number before EO indicates the number of moles of ethylene oxide added; the same applies hereinafter), and polyoxyethylene (3EO) alkyl (any of 11-15 carbon atoms or a mixture of two or more) ether sulfate sodium. It may contain any component selected from alkylbenzene sulfonates such as laurylbenzenesulfonate sodium and laurylbenzenesulfonate triethanolamine. It may contain any component selected from polyoxyethylene alkyl ether sulfates such as polyoxyethylene (3EO) tridecyl ether acetate sodium.N-acyl amino acid salts such as sodium coconut oil fatty acid sarcosinate, lauroyl sarcosinate triethanolamine, sodium lauroyl methyl-L-glutamate, sodium coconut oil fatty acid-L-glutamate, coconut oil fatty acid-L-glutamate triethanolamine, sodium coconut oil fatty acid methyl taurate, sodium lauroyl methyl taurate, sodium ether sulfate alkanesulfonate, hydrogenated coconut oil fatty acid glycerin sulfate sodium, hydrogenated coconut oil fatty acid glycerin sulfate sodium, disodium undecinoylamide ethyl sulfosuccinate, sodium octylphenoxydientoxyethyl sulfonate, ole It may contain any component selected from anionic surfactants such as disodium aminosulfosuccinate, sodium dioctyl sulfosuccinate, sodium dioctyl sulfosuccinate, disodium lauryl sulfosuccinate, polyoxyethylene alkyl (carbon chain 12-15) ether phosphate (8-10EO), sodium polyoxyethylene oleyl ether phosphate, sodium polyoxyethylene cetyl ether phosphate, disodium lauryl polyoxyethylene sulfosuccinate, sodium polyoxyethylene lauryl ether phosphate, sodium lauryl sulfoacetate, and sodium tetradecenesulfonate. It may also contain any component selected from cationic surfactants such as stearyldimethylammonium chloride, di(polyoxyethylene)oleylmethylammonium chloride, stearyldimethylbenzylammonium chloride, stearyltrimethylammonium chloride, tri(polyoxyethylene)stearylammonium chloride, polyoxypropylene methyldiethylammonium chloride, myristyldimethylbenzylammonium chloride, and lauryltrimethylammonium chloride.It may contain any component selected from amphoteric surfactants such as 2-alkyl-N-carboxymethyl-N-hydroxyethylimidazolinium betaine, undecylhydroxyethylimidazolinium betaine sodium, undecyl-N-hydroxyethyl-N-carboxymethylimidazolinium betaine, stearyl dihydroxyethyl betaine, coconut oil fatty acid amidopropyl betaine, coconut oil alkyl-N-carboxyethyl-N-hydroxyethylimidazolinium betaine sodium, coconut oil alkyl-N-carboxymethoxyethyl-N-carboxymethylimidazolinium disodium lauryl sulfate, and N-coconut oil fatty acid acyl-L-arginine ethyl-DL-pyrrolidone carboxylate. It may contain any component selected from nonionic surfactants such as polyoxyethylene alkyl (12-14 carbon atoms) ethers (7EO), polyoxyethylene octylphenyl ether, polyoxyethylene oleyl ether, polyoxyethylene oleate glyceryl, polyoxyethylene stearyl ether, polyoxyethylene cetyl ether, polyoxyethylene cetyl stearyl diether, polyoxyethylene sorbitol lanolin (40EO), polyoxyethylene nonylphenyl ether, polyoxyethylene polyoxypropylene cetyl ether, polyoxyethylene polyoxypropylene decyltetradecyl ether, polyoxyethylene lanolin, polyoxyethylene lanolin alcohol, and polyoxypropylene stearyl ether. It may contain any component selected from thickeners such as isostearate diethanolamide, undecylenate monoethanolamide, oleate diethanolamide, beef tallow fatty acid monoethanolamide, hydrogenated beef tallow fatty acid diethanolamide, stearate diethanolamide, stearate diethylaminoethylamide, stearate monoethanolamide, myristic acid diethanolamide, coconut oil fatty acid diethanolamide, coconut oil fatty acid ethanolamide, laurate isopropanolamide, laurate ethanolamide, laurate diethanolamide, and lanolin fatty acid diethanolamide.It may contain any component selected from silicone oils such as linear or cyclic methylpolysiloxane, methylphenylpolysiloxane, dimethylpolysiloxane polyethylene glycol copolymer, dimethylpolysiloxane polypropylene copolymer, amino-modified silicone oil, and quaternary ammonium-modified silicone oil. It may contain any component selected from thioglycolic acid and its salts. It may contain any component selected from cysteamine and its salts. It may contain any component selected from peroxides such as hydrogen peroxide, persulfates, perborates, and urea peroxide. It may contain any component selected from bromates such as sodium bromate and potassium bromate. It may contain any component selected from other active ingredients such as keratolytic agents, astringents, wound healers, deodorants, anti-allergic agents, blood flow promoters, and cell activators.

[0053] By the way, the compositions according to this embodiment, such as topical skin preparations and skin cosmetics, contain the product of Aralia elata treated with the aforementioned enzyme or an extract thereof, and therefore exert anti-aging and anti-aging effects on the skin, maintaining and improving the condition of the skin. Here, maintaining and improving the condition of the skin includes maintaining and / or improving wrinkles, maintaining and / or improving the texture of the skin, and preventing and / or improving dullness of the skin. Specifically, the wrinkle-improving effect is a state in which the number of wrinkles is reduced and the depth of the grooves is made shallower by increasing the flexibility of the skin. The texture-improving effect is an effect that improves the skin to a fine-textured state, that is, a state in which the skin grooves on the skin surface are shallow and each skin ridge is clear, small, and shows a beautiful triangle. Furthermore, the dullness-preventing effect is an effect that acts on the skin area that has lower brightness compared to the surrounding area, which is called dull skin, and reduces the area of ​​dull skin and the degree of decrease in brightness.

[0054] The compositions according to this embodiment, such as topical skin preparations and skin cosmetics, are particularly useful for administration to or application to subjects having at least one of the following symptoms due to aging: wrinkles, dry skin, dull skin, and rough skin texture. Such subjects include, for example, subjects who have factors that make them prone to developing at least one of the following: dry skin, dull skin, and rough skin texture. By applying topical skin preparations and skin cosmetics to subjects having these conditions, it is possible to improve at least one of the following symptoms: wrinkles, dry skin, dull skin, and rough skin texture, and to expect health or cosmetic benefits.

[0055] The dosage and application amount of topical skin preparations and skin cosmetics vary depending on the age, weight, application / administration route, dosage form, and frequency of administration, and can be broadly modified at the discretion of those skilled in the art. Specifically, the application amount or dosage is not particularly limited, but it can be, for example, 0.001 mg / dose to 10 g / dose, converted to the dry weight of the enzyme-treated product or extract of the active ingredient, Aralia elata. Topical skin preparations and skin cosmetics may be administered or applied repeatedly, for example, at intervals of 6 to 24 hours.

[0056] The compositions according to this embodiment are also preferably anti-aging compositions, specifically, compositions that are applied to the skin, such as the topical skin preparations and skin cosmetics exemplified above, and are used to suppress skin aging, such as wrinkles, dry skin, dull skin, and rough skin texture.

[0057] The compositions according to this embodiment are also preferably compositions for improving the activity of the 20S proteasome, and specifically, compositions that are applied to the skin and used to improve the activity of the 20S proteasome in cells present in the skin (particularly fibroblasts), such as the topical skin preparations and skin cosmetics exemplified above. The 20S proteasome has the function of removing abnormal proteins in the body that are produced by oxidative damage caused by reactive oxygen species. For this reason, compositions for improving the activity of the 20S proteasome are useful as compositions having anti-aging effects. As a method for evaluating the activity of the 20S proteasome, the method described in the examples can be exemplified.

[0058] The compositions according to this embodiment are also preferably compositions for promoting the expression of the sirtuin I gene, and specifically, compositions applied to the skin, such as the topical skin preparations and skin cosmetics exemplified above, and used to promote the expression of the sirtuin I gene in cells present in the skin (especially fibroblasts). Sirtuin I has various effects, including anti-aging effects, diabetes improvement effects, cardiovascular protective effects, kidney disease improvement effects, inflammatory cytokine production suppression effects, and neuroprotective effects. Therefore, compositions for promoting the expression of the sirtuin I gene are useful as compositions having the above-mentioned various effects. The expression level of the sirtuin I gene can be evaluated based on the mRNA expression level of the sirtuin I gene, and the method described in the examples can be exemplified as a specific evaluation method. It is preferable to evaluate the mRNA expression level of the sirtuin I gene based on the value obtained by dividing it by the mRNA expression level of an internal standard gene such as the GAPDH gene. [Examples]

[0059] The present invention will be described in more detail below with reference to examples, but the technical scope of the present invention is not limited to the following examples.

[0060] [Example 1] Preparation of test samples and control samples of Aralia elata fermentation decomposition liquid. All of the Aralia elata wood used in this example was sourced from Akita Prefecture. The branches were cut to approximately 5 cm in length, dried overnight at 80°C, and then ground using a pin mill.

[0061] <Manufacturing Example 1> Preparation of Aralia elata enzyme reaction solution 150g of crushed Aralia elata was placed in a sterile bag and sterilized in an autoclave (121°C, 20 minutes) to obtain crushed Aralia elata (autoclave sterilized product).

[0062] Enzymes and water were added to prepare a slurry with the composition shown in Table 1. This slurry was placed in a wide-mouthed bottle and the enzymatic reaction was carried out while stirring. After adjusting the pH to 5 with citric acid, the enzymatic reaction was carried out at 50°C for 16 hours. After the enzymatic reaction, the temperature was raised to 90°C and held for 2 hours to deactivate the enzyme, and the resulting solution was cooled to obtain the enzyme reaction solution. Sumizyme CG (manufactured by Shin Nippon Chemical Industries) used in this reaction is a cellulase derived from filamentous fungi and is added to assist the enzyme activity of microorganisms in microbial fermentation, which will be described later. In addition, as Comparative Example 1, a sample was prepared without enzymes, under the same conditions such as pH, temperature, and stirring.

[0063] [Table 1]

[0064] <Production Example 2> Preparation of pre-culture medium for filamentous fungi in flasks 150 ml of culture medium prepared with the composition shown in Table 2, with the addition of Aralia elata enzyme reaction solution as a nutrient source and enzyme induction agent, was placed in a baffled flask for microbial culture and sterilized at 121°C for 20 minutes. After cooling to the culture temperature, a spore suspension of Aspergillus oryzae strain AO-0101 (spores 10) was prepared. 6 Add 1 mL of (particles / ml) and incubate with shaking at 30°C for 2 days to obtain a filamentous fungal flask pre-culture solution (Production Example 2-1).

[0065] Similarly, Trichoderma reesei strain NBRC31326 and Penicillium purpurogenum strain NBRC4684 were cultured under the same conditions to obtain pre-culture solutions (Preparation Examples 2-2 and 2-3).

[0066] [Table 2]

[0067] <Manufacturing Example 3> Preparation of Japanese angelica tree fermented product The Aralia elata enzyme reaction solution prepared in Production Example 1 was placed in a 3L jar fermenter (Takasugi Seisakusho) and sterilized at 121°C for 20 minutes. The Aspergillus oryzae flask preculture medium prepared in Production Example 2-1 was added to this to achieve the composition shown in Table 3. Fermentation was carried out at 30°C, 0.2 vvm, and 200 rpm for 48 hours, adjusting the pH to 6.0 with 10% sodium hydroxide, to obtain the Aralia elata-Aspergillus ferment (Production Example 3-1). The same procedure was carried out for the other two strains (Production Examples 3-2 and 3-3). As a control group, a sample was prepared under the same conditions except that sterile water was added instead of the flask preculture medium (Comparative Example 2).

[0068] [Table 3]

[0069] <Manufacturing Example 4> Preparation of ethanol extract and freeze-dried product of Aralia elata enzyme reaction 1000g of the fermented product prepared in Production Example 3-1, including the solid content, was weighed out, and the same weight of ethanol was added. Extraction was carried out at room temperature for 16 hours while stirring. After extraction, the solid content was roughly filtered using 7μm filter paper, and then centrifuged in a centrifuge (Tommy Seikou) at 10000 rpm for 10 minutes. Further suction filtration was performed using 1μm glass fiber filter paper to obtain a clear filtrate. The filtrate was concentrated in an evaporator and then freeze-dried using a freeze-dryer to obtain freeze-dried powder (Sample 1) in the amounts shown in Table 4.

[0070] Instead of the fermented product prepared in Production Example 3-1, the same procedure was performed on the samples prepared in Production Example 3-2, Production Example 3-3, Comparative Example 1, and Comparative Example 2 to obtain the samples shown in Table 4.

[0071] [Table 4]

[0072] <Manufacturing Example 5> Preparation of 1,3-butanediol extract from fermented and hydrolyzed Aralia elata To 1000 g of the fermentation decomposition liquor prepared in Production Example 3-1, an equal weight of 1,3-butanediol was added and the mixture was stirred. Extraction was carried out at room temperature for 16 hours. After extraction, the solids were roughly filtered using 7 μm filter paper, then centrifuged at 10,000 rpm for 10 minutes using a centrifuge (Tommy Seikou), and further filtered by suction using 1 μm glass fiber filter paper to obtain a clear filtrate. The filtrate was allowed to stand at 4°C for one week, and then filtered through a 0.45 μm filter to obtain 1620 g of 1,3-butanediol extract from Aralia elata fermentation decomposition product (Sample 4).

[0073] <Comparative Example 3> Preparation of Galactomyces skim milk culture extract and freeze-dried sample In Comparative Example 3, an extract of Galactomyces candidus cultured in skim milk medium was prepared as a control sample for various anti-aging tests and used as a sample for comparative testing. Specifically, a culture medium with the composition shown in Table 5 was prepared as the substrate for pre-culture, placed in a baffled flask, capped with silicose, and sterilized at 121°C for 20 minutes. After sterilization, the pre-culture medium was cooled to 30°C, Galactomyces candidus was inoculated on one platinum loop, and cultured with shaking at 30°C for 48 hours.

[0074] For the main culture, a culture medium was prepared by dissolving 10 g of skim milk, 6 g of glucose, and 0.6 g of yeast extract in 1950 g of purified water. This medium was placed in a small jar fermenter for microbial culture and sterilized at 121°C for 20 minutes. After sterilization, the main culture medium was cooled to 30°C, and 50 g of pre-culture medium was added. Galactomyces candida was cultured at 30°C for 48 hours while continuously adjusting the pH to 6.0 with sodium hydroxide aqueous solution. The resulting skim milk galactomyces culture solution was heat-treated at 121°C for 30 minutes to extract cellular components, and then cooled to room temperature. The resulting solution containing solids was filtered through a pre-filter and then a 0.45 μm membrane filter to obtain a skim milk galactomyces culture solution from which solids had been removed. This was concentrated using an evaporator to obtain 15 g of lyophilized product (comparative sample 3).

[0075] [Table 5]

[0076] The evaluation test methods and results using the various culture media prepared in Example 1 and the comparative example culture media are shown in Example 2 and below. A list of the samples used for evaluation is shown in Table 6.

[0077] [Table 6]

[0078] [Example 2] Effect of improving 20S proteasome activity Fibroblasts were seeded at a rate of 3500 cells / well in a 96-well cell culture plate and cultured to a semi-confluent state (37°C, 5% CO2). The culture medium was then replaced with a medium containing Sample 1 at the concentrations shown in Table 7, and the cells were cultured overnight.

[0079] The supernatant of the plate culture was replaced with Hanks buffer (100 μL / well), and then each well was irradiated with ultraviolet light (UVB) at approximately 20 mJ to ensure uniform exposure. The culture medium was then replaced again with the medium containing sample 1 (0.5% FBS), and the culture was performed for 2 days before analysis. 20S proteasome activity was assessed using the 20S Proteasome Assay kit (Cayman Chemical). The results are shown in Table 7 and Figure 1. Generally, 20S proteasome activity decreases with UVB treatment, but it was shown that it was activated in a concentration-dependent manner by adding fermented Aralia elata extract.

[0080] For comparative samples 1 and 2, which did not undergo a fermentation process, the cell viability and 20S proteasome specific activity were lower in the 25 ppm and 50 ppm addition groups compared to sample 1, which underwent a fermentation process.

[0081] Furthermore, comparative sample 3 (skim milk culture medium) did not show 20S proteasome activity at this concentration, nor was there any improvement in cell viability.

[0082] [Table 7]

[0083] [Example 3] Effect of promoting the expression of sirtuin I (SIRT1) Normal human fibroblast cells NB1RGB (obtained from RIKEN Cell Bank) were placed in a 35mm dish in a 1x10⁶ arrangement. 5 Cells were seeded and cultured for 3 days (37°C, 5% CO2). Sample 1 (freeze-dried fermented hydrolysate of Aralia elata) was dissolved in the culture medium to a concentration of 50 ppm (0.5% FBS), added, and cultured overnight. The supernatant of the plate culture was replaced with Hanks buffer (100 μL / well), and then each well on the dish was irradiated with ultraviolet light (UVB) at approximately 20 mJ to ensure uniform exposure. The culture was then replaced with the sample-added medium again and cultured for 2 days. Cells were detached by trypsin treatment, and the supernatant was removed by centrifugation to collect the cell pellet.

[0084] Total RNA was extracted from the recovered cell pellet using the FastGene RNA Basic Kit (Nippon Genetics). Using this total RNA solution, cDNA was synthesized using the Toyobo ReverTra Ace qPCR RT Master Mix (FSQ-201) and subjected to real-time PCR. Real-time PCR was performed using the Toyobo Thunderbird SYBR qPCR Mix (QPS-201), and the mRNA expression levels of sirtuin I (SIRT1) and GAPDH were measured. Evaluation was performed by dividing the SIRT1 mRNA expression level in each test group by the GAPDH mRNA expression level. The primers for SIRT1 and GAPDH are shown in the table below.

[0085] [Table 8]

[0086] Figure 2 shows the SIRT1 mRNA expression level, divided by the GAPDH mRNA expression level, for cells cultured under the above conditions of UVB irradiation (UVB(+)) and under conditions without UVB irradiation (normal culture).

[0087] [Example 4] Evaluation of moisturizing properties by stratum corneum water content and transepidermal water loss. Using the samples shown in Table 6, lotions with the compositions shown in Table 9 were prepared and applied twice daily to the inner forearms of 10 female subjects aged 40-50 for four weeks. Stratum corneum moisture content was measured before application and at 2 and 4 weeks after application using a Corneometer (Courage+Khazaka), and transepidermal water loss was measured using a Tewameter® (Courage+Khazaka electronic GmbH). The results are shown in Tables 10 and 11.

[0088] [Table 9]

[0089] [Table 10]

[0090] As shown in Table 10, regarding stratum corneum moisture content, an increase in moisture retention was observed in test groups 1-1, 1-2, and 1-3 compared to control group 4, which used purified water. The fermented hydrolysate extract (test groups 1-1, 1-2, and 1-3) had higher moisturizing power than the stratum corneum extract (control group 1), and showed a stratum corneum moisture retention effect equivalent to or better than that of skim milk culture solution (control group 2).

[0091] [Table 11]

[0092] Furthermore, as shown in Table 11, while an increase in transepidermal water evaporation was observed in control group 4 (purified water) during the test period due to environmental influences, the inhibitory effect on transepidermal water evaporation was confirmed in the other test groups and the control group.

[0093] [Example 5] Skin texture improvement test 1 A lotion with the composition shown in Table 9 was applied twice a day for four weeks to the inner forearm of 10 female subjects aged 40-50, marking a 15mm x 15mm area in each test section. The skin texture before and after application was photographed using a microscope (manufactured by Keyence Corporation) and compared. The images were evaluated on the following three items (depth of skin furrows, shape of skin ridges, and size of skin ridges) using the following five-point scale, and the average scores of the 10 subjects are shown in Tables 12-14.

[0094] (1) Depth of skin furrows 5. The skin furrows are very shallow. 4. The skin furrows are somewhat shallow. 3. Skin furrows are of normal size. 2. The skin furrows are somewhat deep. 1. The skin furrows are very deep.

[0095] (2) Shape of the dermal ridges 5. They are all perfect triangles. 4. It is almost triangular. 3. Skin ridges other than triangular ones are somewhat prominent. 2. Skin ridges other than triangles are prominent. 1. Pedicles other than triangular ones are very prominent.

[0096] (3) Size of the dermal ridges 5. Very small and neat 4. Slightly small 3. It is of medium size. 2. Slightly large 1. Very large

[0097] [Table 12]

[0098] [Table 13]

[0099] [Table 14]

[0100] As shown in Tables 12-14, compared to the control group 4 using purified water, the scores were best in the order of Test Group 1-1, Test Group 1-2, Test Group 1-3, Control Group 1, and Control Group 2. Excellent skin texture improvement effects were confirmed with the Aralia elata fermentation hydrolysate extract.

[0101] [Example 6] Wrinkle Improvement Test In this Example 6, the samples shown in Table 15 were applied twice a day for four weeks to the left and right cheeks of 10 female subjects in their 40s and 50s. The right cheek was designated as the test group and the left cheek as the control group, and the wrinkle condition before and after application was analyzed using a skin image analysis device (VISIA). TM Table 16 shows the results of numerically evaluating wrinkles using Evolution (manufactured by Canfield).

[0102] [Table 15]

[0103] [Table 16]

[0104] As shown in Table 16, the test group (fermented hydrolysate of Aralia elata) was found to have a greater wrinkle-improving effect than the control group (skim milk culture solution).

[0105] [Example 7] Dullness Improvement Test In this Example 7, the dullness improvement effect was measured in the test group and the control group in parallel with the test in Example 6. Dullness was evaluated using a colorimeter (manufactured by Konica Minolta), and the lightness index L* value in the L*a*b* color system was determined and analyzed. The results before application and after 4 weeks of continuous application are shown in Table 12 (in the table, the L* value is the average value for the subjects (10 people)).

[0106] [Table 17]

[0107] As shown in Table 17, wrinkle-improving effects were confirmed in both the test group (fermented hydrolysate of Aralia elata) and the control group (skim milk culture solution).

[0108] [Example 8] Evaluation of skin firmness (elasticity) (sensory test) In this Example 8, a sensory evaluation of skin firmness was conducted during the tests of Examples 6 and 7. Specifically, evaluations were conducted weekly on the following 5-point scale from week 1 to week 4 after the start of the test. The average of the scores from the 10 subjects is shown in Table 18.

[0109] Review regarding the feeling of skin firmness. 5: Very firm 4: Slightly firm 3: Normal 2: Slightly lacking firmness 1: Very lacking in firmness

[0110] [Table 18]

[0111] As shown in Table 18, the test group containing fermented hydrolysate of Aralia elata as a substrate component showed a greater improvement in skin firmness than the control group containing skim milk culture solution.

[0112] [Example 9] Skin firmness test (skin elasticity improvement test) In this 9th example, to assess skin firmness during the tests of Examples 6 and 7, a skin viscoelasticity measuring device (Cutometer MPA580, Courage+Khazaka) was used. The skin surface was suctioned for a certain period of time through the opening at the tip of the probe under constant negative pressure, and then the skin's height was measured over time as it returned to its original state after the suction was released. The Ur / Uf value (instantaneous recovery rate) was used as a parameter indicating skin elasticity, reflecting age-related changes, skin firmness, and sagging. The value before the start of the test was set to 100, and the ratio to the value after 4 weeks of application was calculated to measure the effect on skin elasticity. The average scores of 10 subjects are shown in Table 19. Measurements were performed after lightly washing the face with a commercially available facial cleanser, followed by 15 minutes of acclimatization in a test room at a temperature of 20±5℃ and humidity of 50±10%. A 4-week rest period was observed between each test group to allow the skin to return to its original state.

[0113] [Table 19]

[0114] [Example 10] Example of lotion production In Example 10, following the formulation in Table 20, ingredients (1) to (10) were stirred at 80°C, dissolved, and then cooled to room temperature to produce a lotion (lotion containing fermented hydrolysate of Aralia elata). A control lotion was also produced in exactly the same manner, except that a skim milk culture solution was added (control lotion 1), and neither was included (control lotion 2).

[0115] [Table 20]

[0116] A sensory evaluation of these lotions was conducted with 10 female subjects aged 40-50. Four items (skin moisture, skin smoothness, skin firmness, and sensory stimulation) were evaluated using the following 5-point scale. The average scores of the subjects (10 people) are shown in Table 21.

[0117] (1) Skin moisture 5: Moisturizing 4: Slightly moist 3: Normal 2: Slightly dry 1: Dry

[0118] (2) Skin smoothness 5: Smooth 4: Slightly smooth 3: Normal 2: Slightly rough 1: Rough

[0119] (3) Skin firmness 5: Very firm 4: Slightly firm 3: Normal 2: Slightly lacking firmness 1: Very lacking in firmness

[0120] (4) Sensory stimulation 5: I don't feel any particular irritation. 4: I feel a slight tingling sensation, but it's not bothersome. 3: You may experience some irritation such as tingling, burning, prickling, or itching, but it is tolerable. 2: The irritation is strong, including tingling, burning, stinging, and itching. 1: The irritation is very strong, including tingling, burning, stinging, and itching. 0: The stimulus is too strong; the test cannot be continued.

[0121] [Table 21]

[0122] As shown in Table 21, the lotion containing fermented hydrolysate of Aralia elata as a substrate component received higher scores in skin smoothness and skin firmness compared to control lotions 1 and 2.

[0123] [Example 11] Manufacture of cream formulation In this Example 11, following the formulation shown in Table 22, a mixture was obtained by mixing and stirring components (1) to (7) at 80°C. A mixture obtained by separately mixing and stirring components (8) to (12) at 80°C was added to this mixture, homogenized, and cooled to room temperature while stirring to produce a cream. The resulting cream was non-greasy during use and left the skin feeling moisturized.

[0124] [Table 22]

Claims

1. A composition for improving the activity of the 20S proteasome and / or promoting the expression of the sirtuin I gene, comprising a hydrophilic organic solvent extract of a fermentation product of Aralia elata reacted with cellulase by Aspergillus oryzae, wherein the hydrophilic organic solvent is a monohydric alcohol or a polyhydric alcohol.

2. The composition according to claim 1, wherein the hydrophilic organic solvent extract is an ethanol extract of the fermented product.

3. The composition according to claim 1, which is a topical skin preparation.

4. The composition according to claim 1, which is a skin cosmetic.

5. A composition according to any one of claims 1 to 4 for anti-aging.

6. A method for producing the composition according to any one of claims 1 to 5, comprising the steps of: culturing Aspergillus oryzae in a culture medium containing Aralia elata reacted with cellulase to obtain a fermented product of Aralia elata by Aspergillus oryzae; and obtaining a hydrophilic organic solvent extract of the fermented product, wherein the hydrophilic organic solvent is a monohydric alcohol or a polyhydric alcohol, and the extract has an effect of improving the activity of the 20S proteasome and promoting the expression of the sirtuin I gene.

Images